Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Indivior PLC    INDV   GB00BRS65X63

INDIVIOR PLC

(INDV)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Indivior PLC : No turn-around in sight

04/07/2021 | 02:58am EDT
long trade
Live
Entry price : 131.5GBX | Target : 160GBX | Stop-loss : 117GBX | Potential : 21.67%
The underlying tendency is to the upside for shares in Indivior PLC and the timing is opportune to get back into the stock. A comeback of the upward dynamic can be anticipated.
Investors have an opportunity to buy the stock and target the GBX 160.
Indivior PLC : Indivior PLC : No turn-around in sight
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
  • The company has solid fundamentals for a short-term investment strategy.

Strengths
  • The group's high margin levels account for strong profits.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • As regards fundamentals, the enterprise value to sales ratio is at 0.56 for the current period. Therefore, the company is undervalued.
  • The company's attractive earnings multiples are brought to light by a P/E ratio at 10.52 for the current year.
  • Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • The tendency within the weekly time frame is positive above the technical support level at 82.5 GBX

Weaknesses
  • The share is close to its long-term resistance in weekly data. Therefore, the potential should be limited. However, a further bullish movement when crossing this resistance will be a positive signal.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart
Subsector Specialty & Advanced Pharmaceuticals
1st jan.Capitalization (M$)Investor Rating
INDIVIOR PLC22.43%1 349
MERCK KGAA5.42%76 963
ZHANGZHOU PIENTZEHUANG PHAR..16.56%28 846
KYOWA KIRIN CO., LTD.16.74%16 228
SK BIOPHARMACEUTICALS CO., ..-33.73%7 860
BETTA PHARMACEUTICALS CO., ..-8.57%6 220
YUHAN CORPORATION-12.38%3 844
RECIPHARM AB (PUBL)6.02%2 766
-
DOTTIKON ES HOLDING AG10.47%2 735
SHENZHEN CHIPSCREEN BIOSCIE..-1.81%2 285
SUPERNUS PHARMACEUTICALS, I..26.59%1 686
More Results

© MarketScreener.com 2021

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials (USD)
Sales 2021 656 M - -
Net income 2021 108 M - -
Net cash 2021 610 M - -
P/E ratio 2021 16,4x
Yield 2021 -
Capitalization 1 349 M 1 349 M -
EV / Sales 2021 1,13x
EV / Sales 2022 0,94x
Nbr of Employees 788
Free-Float 98,6%
Upcoming event on INDIVIOR PLC
05/05/21
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 3,28 $
Last Close Price 1,84 $
Spread / Highest target 141%
Spread / Average Target 78,9%
Spread / Lowest Target 42,0%
EPS Revisions
Managers and Directors
NameTitle
Mark Crossley Executive Director, CEO & COO
Ryan Preblick Chief Financial Officer & Executive Director
Graham C. Hetherington Chairman
Christian Heidbreder Chief Scientific Officer
Murali Gopal Chief Medical Officer